A European group of university laboratories and scientists working for industrial SME companies, combining integrated systems biology and comparative genomics in order to study ageing of the human brain and/or the most common age-related diseases.

    Particular attention is paid to Alzheimer’s disease with the aim of identifying and validating new molecular targets and new biomarkers.



    CARMMA is based on the new hypothesis that the comorbidities of obesity are related premature senescence of adipose tissue (AT).

    The primary objective of CARMMA is to define the mechanisms through which AT senescence contributes to the initiation and progression of the target comorbidities in the project, which are metabolic cardiomyopathy and sarcopenia.


    INSERM TRANSFERT has developed unique expertise in the development and negotiation of public/private partnerships (PPP) linked to research projects involving human beings (in particular, cohorts, biobanks and clinical studies).

    As an example, the Constances project, a “generalist” epidemiological cohort study made up of a representative sample of 200,000 adults between 18 and 69 years old at inclusion who consulted social security health examination centres (HEC), with the aim of monitoring several parameters: “Health of the elderly and ageing, women’s health, cardiovascular disorders, inflammatory and chronic diseases, behaviour and the role of the environment in health”.



    The overall objective of this project is to develop and provide rapid, ambulatory diagnostic tools which will considerably increase our ability to manage the current situation with Ebola virus in West Africa and best prepare us for future epidemics.

    EbolaMoDRAD is also setting up a programme to increase capacity in West Africa and practical training in non-endemic countries (neighbouring countries to endemic areas) in the fields of managing epidemics, diagnosis and the application of tools/results from EbolaMoDRAD.


  • EBOVAC 2

    The EBOVAC2 project is intended to assess the safety and efficacy of a new preventative vaccine regimen against EVD.

    EBOVAC2 will provide solid data on the safety and immunogenicity of the regimen and the immune response to vaccines will be compared at different administration intervals. To do this, phase 2 studies have been conducted in Burkina Faso, the Ivory Coast, France, Rwanda, Uganda and the United Kingdom.


  • EE-ASI

    The EE-ASI project is an innovative ASI approach which combines technologies brought by academic partnerships and two SMES.

    A T cell epitope which targets the beta cell will be combined with tolerogenic IL-10 cytokine which will target cells presenting the antigen through gold nanoparticles and will be delivered into very superficial layers of the skin using microbore needles. Validation of manufacture and in vitro and in vivo efficacy will firstly be demonstrated and will then followed by a phase 1 clinical study in order to confirm its safety in human beings.


  • EHVA

    The aim of EHVA is to develop several innovative concepts in vaccines against HIV, both for prophylaxis and treatment.

    The prophylactic vaccine strategy is based on a the development of new candidate vaccines and a vaccination system which is able to improve protective antibody responses, whereas the approach to a therapeutic vaccine will examine the measures which contribute to developing a functional cure, combining vaccines with other immunological interventions.



    This project will help to construct and assess a stratified health promotion programme based on so-called “omics” technologies for patients suffering from an endocrine form of hypertension.

    We will define the specific “omic” profiles for patients suffering from primary hyperaldosteronism, pheochromocytoma/functional paraganglioma and Cushing syndrome by combining high output genetic, genomic and metabolometric data, the effects being annotated with bioinformatics modelling. The profiling based on so-called “omics” technologies should help in the early identification of patients with preclinical phenotypes and hypertensive patients who are grouped into endocrine groups and who may benefit from personalised treatment.




    ERINHA is a research infrastructure intended to improve European preparation and response, in terms of research, to combat highly infectious emergent and re-emergent diseases.

    The aim of the preparatory phase of ERINHA is to reach the necessary maturity to successfully set up the infrastructure and ensure that the operational phase begins.



    The Team run by Camille Locht, Inserm Research Director and Director of Inserm U1019, located in the Pasteur Institute in Lille, has developed an attenuated strain of Bordetella pertussis with the aim of developing a new effective vaccination vector against various pathogens, particulary the pathogen responsible for whooping cough.

    The Strain has been shown to be safe in a phase 1 clinical study conducted in Sweden as part of European consortium FP6. In 2014 Inserm Transfert granted the young American company ILiAD a specialist in whopping cough, a licence for the exclusive worldwide marketing of the technology, protected by a large portfolio of patents covering several therapeutic and prophylactic applications.  A collaborative agreement was also set up between the IliAD Company and Inserm Transfert to support the development of a first vaccination product as part of a clinical study sponsored by Inserm.



    IMMUNOSCORE® measures the density of two T lymphocyte populations – CD8 and CD3 – which are found within and at the periphery of tumours.

    The technique combines immunohistochemistry and image analysis and is based on 5 families of patents submitted since 2005 (approximately 70 patents and patent submissions), representing an initial investment of 600,000 Euros and including the IP strategy and assistance with functional validation and procurement of informatics materials. The HalioDx Company is now developing reagents used in the composition of the kit in order to guarantee robust reliable labelling but is also working on image analysis software to create the Immunoscore®, a simple standardised quantitative test for a new stratification of patients for precision medicine.


  • JPND

    The European programme – “Research into neurodegenerative diseases” (JPND) is the largest worldwide research initiative intended to respond to the challenge of the neurodegenerative diseases.

    The aim of JPND is to increase the coordinated investment between companies taking part in the research into the causes, treatments and appropriate resources to care for people suffering from neurodegenerative diseases.



    Since 2011, MedImmune, the AstraZeneca international biological substances unit, has contributed to the advancement of Inserm laboratory research in several therapeutic areas, including oncology, respiratory and inflammatory diseases and autoimmune diseases.

    This exploratory research is dedicated to translational biology, the discovery of new pathophysiological mechanisms and assesses candidate drug potentials.  This partnership is based on around ten research projects conducted in close scientific cooperation by the two partners and draws on the combined expertise of the Inserm biologists’ teams and clinicians, bringing together understanding of human diseases and access to patients.



    The primary objectives of MEDIT-AGEING are to improve early detection of Alzheimer’s disease and the understanding of its pathophysiological mechanisms by examining the impact of internal/external determinants such as genetics and lifestyle and the effects and mechanisms of the action of training on mental health and wellbeing in the elderly.



    METACARDIS is developing an approach to systemic medicine at several levels in order to identify biological relationship between the intestinal microbiota as assessed by metagenomics and the regulation of host genome expression, which will improve understanding and new treatments for cardiometabolic diseases and their comorbidities. These studies will help to identify new molecular targets, biomarkers and predictors for progression of cardiometabolic diseases, opening the way towards personalised medicine in this field.



    The Team run by Didier Letourneur, CNRS Research Director and Director of Inserm U1148, located in Paris and awarded the George Winter Prize from the European Biomaterials Society, has developed a natural biocompatible hydrogel which is biodegradable of variable and controlled pore size, and which can be produced in different forms (microbeads, dressings, etc.).  This biomaterial is protected by several patent applications and offers the ability to develop numerous human health applications, such as those already demonstrated in animals for bone reconstitution and delivery of cells and molecules.  In 2016 Inserm Transfert granted an Exclusive Marketing Licence to the SILTISS Company for this technology with the aim of developing medical devices for several applications in regenerative medicine.  SILTISS is a subsidiary of the SILAB group and now has the financial and operational power of its parent company, which provides it with premises, clean rooms and a wide range of expertise, particularly that of its R&D teams.


WordPress Lightbox